Role of adipokines in the formation of metabolic disorders in conditions of metabolic-associated fatty liver disease (MAFLD)

Abstract

The aim of this review is to summarise the current knowledge on the role of adipokines on the development and progression of MAFLD. Discussion: diagnostic criteria for metabolic-associated liver disease (MAFLD) versus non-alcoholic fatty liver disease (NAFLD) are presented. The pathogenetic aspects of metabolic disorders in MAFLD are discussed. The potential role of various adipokines such as leptin, resistin, vasfastin, ghrelin, adiponectin and others is considered. Data from our own studies and foreign studies are presented. Conclusion: given the pandemic growth of MAFLD and its association with cardiovascular risk and obesity, the question of how to properly curate patients with comorbid to reduce risks is timely and highly relevant. Adipokines contribute significantly to the pathogenesis of MAFLD. Among all, leptin and adiponectin are the most promising and well studied. That is why strategies aimed at restoring leptin and adiponectin balance may have an impact on the course of MAFLD.